Sichuan Kelun‑Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced annual results for 2025, with full‑year revenue reaching RMB 2.058 billion (≈ US$298 million) and gross profit of RMB 1.479 billion (≈ US$214 million), while advancing a differentiated R&D pipeline spanning bispecific ADCs, radionuclide drug conjugates (RDCs), immune‑stimulating ADCs (iADCs), and degrader‑antibody conjugates (DACs) – positioning the company for business transformation from clinical‑stage to commercial‑stage biopharma.
Margin Expansion Potential: 71.9% gross margin with manufacturing scale‑up and biosimilar/ADC platform efficiencies; path to operating breakeven 2027‑2028 assuming pipeline advancement without major dilutive financing.
Platform Diversification Strategy:OptiDC platform (ADC backbone) enables modular expansion into RDC, iADC, DAC formats; non‑oncology diversification (autoimmune, metabolic) reduces oncology‑concentration risk; global competitiveness positioning through differentiated modalities.
Competitive Positioning: vs. RemeGen (TROP2 ADC focus) – Kelun‑Biotech broader modality diversity; vs. Henlius (biosimilar‑heavy) – Kelun‑Biotech innovation‑focused; SKB103 bispecific ADC and SKB264 TROP2 ADC provide first‑in‑class/best‑in‑class potential vs. crowded monospecific ADC landscape.
Capital Markets Strategy: HKG:6990 listing provides RMB/HKD financing flexibility; adjusted loss narrowing supports valuation re‑rating from clinical‑stage to commercial‑stage multiples; potential secondary offering or partnership monetization (ex‑China rights) to fund Phase III pipeline.
Forward‑Looking Statements This brief contains forward‑looking statements regarding revenue growth projections, margin expansion timelines, and pipeline advancement expectations for Kelun‑Biotech. Actual results may differ due to NRDL pricing pressures, competitive dynamics in the ADC market, and clinical trial outcomes for next‑generation modalities.-Fineline Info & Tech
By Fineline Cube 